# Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

> **NCT00161031** · NA · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 30 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Atomoxetine

## Key facts

- **NCT ID:** NCT00161031
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161031, "Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00161031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*